Drugs / Euflexxa
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06463132 | Nov 2024 → Nov 2025 | osteoarthritis, knee | Rion Inc. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01895959 | Aug 2013 → Nov 2016 | osteoarthritis, knee | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EUFLEXXA | “with and without EUFLEXXA, for the treatment of Knee Osteoarthritis” NCT06463132 ↗ |
| Route | Other | “single intra-articular injections of PEP reconstituted with 0.9% Normal Saline at a low dose (one vial PEP) and high dose (two vials PEP), with and without EUFLEXXA” NCT06463132 ↗ |